Phase ll Study of HEC585 in Patients With IPF

NCT05060822 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: HEC585
DRUG: Pirfenidone
DRUG: Placebo

Sponsor

Sunshine Lake Pharma Co., Ltd.